Abciximab

Abciximab
Monoclonal antibody
Type	Fab fragment
Source	Chimeric (mouse/human)
Target	CD41 7E3
Clinical data
Trade names	Reopro
Other names	Abcixifiban, c7E3 Fab
AHFS/Drugs.com	Monograph
License data	US DailyMed: Abciximab; US FDA: Abciximab;
Routes of; administration	Intravenous (IV)
ATC code	B01AC13 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only); US: ℞-only;
Identifiers
CAS Number	143653-53-6 ;
DrugBank	DB00054 ;
ChemSpider	none;
UNII	X85G7936GV;
KEGG	D02778 ;
ChEMBL	ChEMBL1201584 ;
Chemical and physical data
Formula	C2101H3229N551O673S15
Molar mass	47456.03 g·mol−1
	(what is this?) (verify)

Abciximab, a glycoprotein IIb/IIIa receptor antagonist manufactured by Janssen Biologics BV and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. It is a glycoprotein IIb/IIIa inhibitor.

While abciximab has a short plasma half-life, due to its strong affinity for its receptor on the platelets, it may occupy some receptors for weeks. In practice, platelet aggregation gradually returns to normal about 96 to 120 hours after discontinuation of the drug. Abciximab is made from the Fab fragments of an immunoglobulin that targets the glycoprotein IIb/IIIa receptor on the platelet membrane.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.